Here in this study, we tested the possibility of domatinostat, a class I-selective HDAC inhibitor in clinical and preclinical stages of development for the treatment of cancer, as an inhibitor of FOXM1 expression in ovarian cancer cells. Here, HDAC9 is linked to ovarian cancer.